Last updated: 2026-10-14 10:38:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Bausch + Lomb Corporation (BLCO) operates in the OPHTHALMIC GOODS sector and is listed on NYSE. The stock is currently priced at $15.81, with a market capitalization of $5.74B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.44 to $18.92. This page covers its latest market performance, valuation, price trends and company information.
$5.74B | |
$15.81 | |
$21.95 | |
$10.45 | |
$15.81 | |
53.00 | |
441.09K | |
-- | |
$18.92 | |
$14.44 | |
-- | |
-- |
Bausch + Lomb Corporation (BLCO) is trading at $15.81 in pre-market trading as of 2026-10-14 09:54:00, down 0.03% ($0.00) from the previous close of $15.81
Pre-market trading shows how investors are pricing BLCO before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Bausch + Lomb Corporation (BLCO) moved from $17.17 to $15.81, representing a decline of 7.94% ($1.36).
The stock traded between $15.47 and $17.50 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 776.62 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 30.5%
BLCO is currently trading at $15.81, placing it 30.5% of the way from its 52-week low of $14.44 to its 52-week high of $18.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
| Industry | OPHTHALMIC GOODS |
| Employees | 13000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Bausch + Lomb Corporation (BLCO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.